<code id='8DC119119E'></code><style id='8DC119119E'></style>
    • <acronym id='8DC119119E'></acronym>
      <center id='8DC119119E'><center id='8DC119119E'><tfoot id='8DC119119E'></tfoot></center><abbr id='8DC119119E'><dir id='8DC119119E'><tfoot id='8DC119119E'></tfoot><noframes id='8DC119119E'>

    • <optgroup id='8DC119119E'><strike id='8DC119119E'><sup id='8DC119119E'></sup></strike><code id='8DC119119E'></code></optgroup>
        1. <b id='8DC119119E'><label id='8DC119119E'><select id='8DC119119E'><dt id='8DC119119E'><span id='8DC119119E'></span></dt></select></label></b><u id='8DC119119E'></u>
          <i id='8DC119119E'><strike id='8DC119119E'><tt id='8DC119119E'><pre id='8DC119119E'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:focus    Page View:1
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In